Crossmark

Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance

Crossref DOI link: https://doi.org/10.1186/s13073-022-01121-y

Published Online: 2022-10-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alkhatib, Heba

Rubinstein, Ariel M.

Vasudevan, Swetha

Flashner-Abramson, Efrat

Stefansky, Shira

Chowdhury, Sangita Roy

Oguche, Solomon

Peretz-Yablonsky, Tamar

Granit, Avital

Granot, Zvi

Ben-Porath, Ittai

Sheva, Kim

Feldman, Jon

Cohen, Noa E.

Meirovitz, Amichay

Kravchenko-Balasha, Nataly https://orcid.org/0000-0001-6943-7479
Funding

Funding for this research was provided by:

Israel Science Foundation (1961/19)

National Cancer Institute NIH (U01 CA238720)
License Information

Text and Data Mining valid from 2022-10-20

Version of Record valid from 2022-10-20
More Information

Article History

Received: 20 January 2022

Accepted: 28 September 2022

First Online: 20 October 2022

Declarations

:

: All in-vivo experiments were performed with the approval of the Hebrew University of Jerusalem IACUC, ethics committee-research number: MD-20-16116-5. NIH approval number: OPRR-A01-5011. The study was conducted in accordance with the protocol, good practice guidelines, and in accordance with regulations of the Authority For Biological and Biomedical Models at the Hebrew University of Jerusalem.All experimentation involving human samples was approved by the Ethics Committee of the Hebrew University-Hadassah Medical School (approval no.: 0346-12-HMO) and was conducted under the provisions of the Declaration of Helsinki. Informed consent was obtained from all study participants.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below